Known contraindication to receive cetuximab or irinotecan at the planned dosesXx_NEWLINE_xXAnti-cancer chemotherapy or biologic therapy if administered prior to the first planned dose of study medication (napabucasin or FOLFIRI) within period of time equivalent to the usual cycle length of the regimen. An exception is made for oral fluoropyrimidines (e.g. capecitabine, S-1), where a minimum of 10 days since last dose must be observed prior to the first planned dose of study medication. Standard dose of bevacizumab (5 mg/kg) may be administered prior to FOLFIRI infusion, per Investigator decision, for as long as permanent decision to include or exclude bevacizumab is made prior to patient randomization. Radiotherapy, immunotherapy (including immunotherapy administered for non-malignant diseaseneoplastic treatment purposes), or investigational agents within four weeks of first planned dose of study medication, with the exception of a single dose of radiation up to 8 Gy (equal to 800 RAD) with palliative intent for pain control up to 14 days before randomization.Xx_NEWLINE_xXThe patient has elective or planned major surgery to be performed during the course of the clinical trialXx_NEWLINE_xXPatients must have completed neoadjuvant taxane +/- anthracycline; patients must NOT have received cisplatin or carboplatin or capecitabine as part of their neoadjuvant therapy regimen\r\n* NOTE: Patients who received preoperative therapy as part of a clinical trial may enroll\r\n* NOTE: Patients that were not able to complete their planned neoadjuvant chemotherapy for any reason (i.e. toxicities, etc.) are eligible to participate as long as no further systemic standard of care therapy is planned by the treating physicianXx_NEWLINE_xXNo other planned concurrent investigational agents or other tumor directed therapy (chemotherapy, radiation) while on studyXx_NEWLINE_xXClinical stage >= T2NxM0 or TanyN+ disease for which radical or partial nephrectomy is plannedXx_NEWLINE_xXPlanned neoadjuvant treatment with anthracycline and taxane containing chemotherapyXx_NEWLINE_xXPlanned surgery or radiation therapy during protocol treatmentXx_NEWLINE_xXSystemic corticosteroid use within 7 days before planned start of study therapyXx_NEWLINE_xXElective or planned major surgery to be performed during the course of the trialXx_NEWLINE_xXPrior neoadjuvant chemo or biologic therapy for current breast cancer within 4 weeks prior to planned surgery [Period 1]Xx_NEWLINE_xXAmong patients with multiple sites of metastatic disease, the other sites that will not be treated on this protocol have either been previously treated or are planned for local treatmentXx_NEWLINE_xXPatients with elective or planned major surgery to be performed during the course of the clinical trialXx_NEWLINE_xXUsing an effective means of contraception that is planned to continue for the duration of treatment and for a further 3 months.Xx_NEWLINE_xXPlanned palliative procedures for alleviation of bone painXx_NEWLINE_xXDiagnosis of another malignancy within 2 years before planned first dose of study drug, except for superficial skin cancers, or localized, low grade tumorsXx_NEWLINE_xXAny other cancer treatments within 2 weeks of planned study treatmentXx_NEWLINE_xXUse of potent inhibitor or inducer of CYP3A4/3A5 within 14 days of planned study treatment or expected requirement for use of such a drug during studyXx_NEWLINE_xXRecent (within 4 weeks of registration), current, or planned participation in another experimental drug studyXx_NEWLINE_xXCurrent, recent (within 28 days prior to Day 1), or planned use of any antitumor therapy outside this studyXx_NEWLINE_xXPatients must have surgery planned to remove the desmoid tumor and either:Xx_NEWLINE_xXPatients must be able to cooperate fully with all planned protocol therapyXx_NEWLINE_xXPlanned procedure or surgery during the studyXx_NEWLINE_xXOngoing or planned systemic anti-cancer therapy or radiation therapyXx_NEWLINE_xXPlanned to receive Erbitux™ (Cetuximab) or similar targeted therapy between Baseline and 6 weeks post-RTXx_NEWLINE_xXInclusion Criteria:\n\n          -  Disease Related\n\n               -  Patients must have documented history of histologically confirmed solid tumors\n                  (as defined by ASCO/CAP guidelines) originating in breast, pancreas, prostate,\n                  lung, colon, esophagus, liver, or ovary, and lymphomas, which are locally\n                  advanced or metastatic and who are refractory or intolerant beyond primary\n                  treatment for their malignancy, or for lymphoma patients who are not eligible for\n                  or who have refused autologous or allogenic hematopoietic stem cell transplant\n\n               -  Measurable or evaluable disease documented within one month of the planned\n                  protocol treatment (Treatment Period Cycle 1, Day 1)first dose of study drug (PK\n                  Period Day 1)\n\n               -  ECOG performance score of 0 and 1\n\n               -  Able to swallow capsules/tablets\n\n        Demographic • Male and females who are 18 years or older\n\n        Laboratory Values\n\n          -  Hemoglobin ? 9.0 g/dL\n\n          -  Absolute neutrophil count ? 1500/uL\n\n          -  Platelet count ? 100,000/uL\n\n          -  Serum creatinine ? 1.5 mg/dL or a 24-hour calculated estimated creatinine clearance of\n             ? 60 mL/min\n\n          -  Serum bilirubin ? 1.5 mg/dL\n\n          -  Serum albumin ? 3g/dL\n\n          -  AST (SGOT), ALP and ALT (SGPT) ? 2.5 times upper limit of normal (OR ? 5 times ULN in\n             the presence of known liver metastases)\n\n          -  Prothrombin time (PT)/International Normalized Ratio (INR) and partial thromboplastin\n             time (PPT) ? 1.5 times the upper limit of normal\n\n          -  Serum sodium, potassium, magnesium, calcium and phosphorous levels within\n             institutional normal limits; supplements required to maintain normal electrolyte\n             levels will be permitted\n\n        Ethical\n\n        • Before any study-specific procedure, the appropriate written informed consent must be\n        obtained\n\n        Exclusion Criteria:\n\n        Disease Related\n\n          -  Clinical or radiographical evidence of active brain metastasis\n\n          -  Patients who have not recovered to ? grade 1 toxicities except grade 2 alopecia or\n             neuropathy associated with previous chemotherapy, radiotherapy, biologic, hormone or\n             prior investigational therapies.\n\n        Medications:\n\n          -  Chemotherapy or other cancer, radiation or surgical treatments within 2 weeks or five\n             half-lives (whichever is shorter) of the first dose of study drug (PK Period Day 1)\n             planned first protocol treatment (i.e., cycle 1 day 1) or not yet recovered from\n             respective treatments\n\n          -  Patients who have had allogenic hematopoietic stem cell transplant or allogenic bone\n             marrow transplant\n\n          -  Patients who have had prior solid organ transplant\n\n          -  Patients who are on immune suppression drugs or anti-transplant rejection drugs\n\n        General:\n\n          -  History of any medical or psychiatric condition or addictive disorder, or laboratory\n             abnormality that in the opinion of the investigator, may increase the risks associated\n             with study participation or treatments that may interfere with the conduct of the\n             study or the interpretation of study results\n\n          -  Prior history of clinically significant gastrointestinal bleeding, intestinal\n             obstruction or gastrointestinal perforation within 6 months before planned initiation\n             of study treatment\n\n          -  Uncontrolled diabetes\n\n          -  History of long QT syndrome or clinically significant cardiac arrhythmia, other than\n             stable atrial fibrillation\n\n          -  Mean QTcF > 450 msec in men and mean QTcF > 470 msec in women at screening\n\n          -  Myocardial infarction within the previous 6 months before planned initiation of study\n             treatment\n\n          -  Active infection requiring intravenous antibiotics within 2 weeks of the first dose of\n             study drug (PK Period Day 1) before planned initiation of study treatment\n\n          -  Prior history or current positive tests for hepatitis B, hepatitis C or human\n             immunodeficiency virus\n\n          -  Currently enrolled in or has not yet completed at least 30 days since ending other\n             investigational device or drug study before planned date of first dose, or the patient\n             is currently receiving other investigational agent(s)\n\n          -  Pregnant, planning a pregnancy or breast feeding during the study\n\n          -  Male or female not willing to use adequate contraceptive precautions during the study\n             period\n\n          -  Unwilling or unable to comply with study requirements or not available for follow-up\n             assessments\n\n          -  Any disorder that compromises the ability of the patient to give written informed\n             consent and/or to comply with study procedures.Xx_NEWLINE_xXThe patient has elective or planned major surgery to be performed during the course of the clinical trialXx_NEWLINE_xXCurrent, recent (within 4 weeks of the first dose of this study), or planned participation in an experimental drug study with an experimental agentXx_NEWLINE_xXPatients who have received another cancer therapy within 2 weeks before the planned day for the apheresisXx_NEWLINE_xXPatients who receive or are planned to receive any other investigational product within the 3 weeks before the planned day for the first NKR-2 administrationXx_NEWLINE_xXLast dose of AZA or DAC within 6 months before the planned date of randomization; however, must be off these treatments for ? 4 weeks before randomizationXx_NEWLINE_xXNew onset seizures (within 3 months before planned randomization) or poorly controlled seizuresXx_NEWLINE_xXTreatment with cytarabine at any dose, lenalidomide, or any other therapy targeted to the treatment of MDS (other than growth factors and other supportive care measures) within 4 weeks of planned randomizationXx_NEWLINE_xXInvestigational therapy within 4 weeks of planned randomizationXx_NEWLINE_xXPlanned use of prophylactic donor lymphocyte infusion (DLI) therapy.Xx_NEWLINE_xXPlanned preemptive/prophylactic administration of donor lymphocytes (as per section 2.5.2)Xx_NEWLINE_xXPatients receiving immunotherapy for non-cancer related treatment within < 4 weeks of first planned dose of study treatment will be excluded.Xx_NEWLINE_xXPrior or planned androgen deprivation or bilateral orchiectomyXx_NEWLINE_xXPatients planned to receive immune checkpoint inhibitor with contra-indications to receive immunotherapyXx_NEWLINE_xXPrior (within last 6 months) or future planned therapeutic surgery for the treatment of the existing lung cancerXx_NEWLINE_xXHistologic confirmation of breast cancer resected by mastectomy with or without immediate reconstruction and chest wall and regional nodal irradiation plannedXx_NEWLINE_xXCurrent or planned glucocorticoid therapy, with the following exceptions:Xx_NEWLINE_xXPlanned concurrent chemotherapy or anti-tumor agent during PCIXx_NEWLINE_xXAny endoscopically-visualized abnormalities such as ulcers, masses or nodules. Neoplastic nodules must first be treated with EMR ?6 weeks prior to planned treatment under this protocol.Xx_NEWLINE_xXSubject has high-risk features (e.g., based on Gleason score, PSA, clinical stage, % positive biopsies), and the treating physician feels the subject should undergo radical prostatectomy sooner than planned within the protocolXx_NEWLINE_xXPatients receiving a donor lymphocyte infusion within 4 weeks of planned T cell infusionXx_NEWLINE_xXPatients receiving a donor lymphocyte infusion within 4 weeks of planned T cell infusionXx_NEWLINE_xXPatients who have the ability to collaborate planned follow-upXx_NEWLINE_xXPlanned treatment with the LR-IUD for CAH or grade 1 EC by primary physicianXx_NEWLINE_xXOnly patients for whom their neuro-oncologist has planned to give bevacizumab and temozolomide 50mg/m^2/day as part of their treatment are eligible for this studyXx_NEWLINE_xXTREATMENT WITH SJCAR19: Prior to planned SJCAR19 infusion, patients with a history of prior allogeneic HCT must be at least 3 months from HCT, have no evidence of active GVHD and have not received a donor lymphocyte infusion (DLI) within the 28 days prior to planned infusionXx_NEWLINE_xXPatients with MRI or clinical evidence of uncontrolled tumor mass effect are excluded; the assessment of mass effect should be made by the study chairs and study neurosurgeons prior to any planned CED treatment.Xx_NEWLINE_xXHematopoietic cell transplant or other cellular based therapy within 30 days before the planned start of study treatment or patients with active graft-vs-host disease with the exception of Grade 1 skin involvementXx_NEWLINE_xXPrior irradiation to the planned radiation target lesion.Xx_NEWLINE_xXPatients who have been treated with chemotherapy or radiation for the purpose of induction, re-induction or consolidation, within two weeks of planned study enrollmentXx_NEWLINE_xXElective procedure (colectomy, gynecological, or thoracic) where at least one vessel is planned to be transected by the ENSEAL X1 device per its instructions for use;Xx_NEWLINE_xXAutologous transplant within 6 weeks of planned CAR-T cell infusion.Xx_NEWLINE_xXAny planned pleurodesis as part of the surgical procedure.Xx_NEWLINE_xXInterval between the hysterectomy and planned start of radiotherapy exceeding 16 weeksXx_NEWLINE_xXPlanned adjuvant focal therapy including additional radiation therapy to the brainXx_NEWLINE_xXPatients who are receiving or are planned to start topical chemotherapeutics, retinoids or imiquimod to other lesions that are not planned for enrollment are eligible; however, the lesion being considered for enrollment should not be under active therapy with these topical agents immediately prior to enrollment.\r\n* Use of topical chemotherapeutics, retinoids or imiquimod on the lesion that is a candidate for enrollment must be halted at least 24 hours prior to enrollment in the study.Xx_NEWLINE_xXHas a known history of hypertensive crisis or hypertensive encephalopathy within 6 months prior to planned start of study drugXx_NEWLINE_xXThe participant has electively planned or will require major surgery during the course of the study.Xx_NEWLINE_xXPlanned palliative procedures for alleviation of bone pain such as radiation therapy or surgeryXx_NEWLINE_xXSubjects must not have received chemotherapy within 2 weeks of planned first (1st) day of radiation therapy (RT)Xx_NEWLINE_xXHave up to five measurable (by Response Assessment in Neuro-Oncology Criteria [RANO]) brain metastasis planned for stereotactic radiosurgeryXx_NEWLINE_xXPlanned vacation or dental work during the study phaseXx_NEWLINE_xXHave electively planned or will require major surgery during the course of the study.Xx_NEWLINE_xXCurrent, recent (within 4 weeks of the administration of this study agent), or planned participation in another experimental therapeutic drug studyXx_NEWLINE_xXDeemed eligible for additional partial resection by treating physician and determined to be safe to receive 3 months of neoadjuvant therapy before planned surgeryXx_NEWLINE_xXParticipating in a chronic transfusion program (pre-planned series of transfusions for prophylactic purposes)Xx_NEWLINE_xXPlanned treatment site(s) accompanied by objective evidence of secondary radiculopathy or neurologic compromiseXx_NEWLINE_xXPlanned treatment site(s) associated with spinal cord compression or canal compromise requiring decompressionXx_NEWLINE_xXPlanned radiation treatments at Mayo Clinic RochesterXx_NEWLINE_xXEvidence of an infection within 7 days of planned injection.Xx_NEWLINE_xXUse of parenteral (IV or intramuscular [IM]) antibiotics (antibacterials, antivirals, anti-fungals, or anti-parasitic agents) within 14 days prior to planned start of therapyXx_NEWLINE_xXCurrent, recent (within 3 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer studyXx_NEWLINE_xXMust have had a relapse or progressive disease (PD) after having received 2 or more prior lines of systemic therapy. Note: A line of therapy is defined as 1 or more cycles of a planned treatment program; this may consist of 1 or more planned cycles of single-agent therapy or combination therapy, as well as a sequence of treatments administered in a planned manner. For example, a planned treatment approach of induction therapy followed by autologous stem cell transplantation (SCT), followed by maintenance is considered 1 line of therapy. Typically each line of therapy is separated by PD.Xx_NEWLINE_xXHad bortezomib and/or carfilzomib intolerance (defined as discontinuation because of drug-related adverse events (AEs) before completion of the planned treatment course) without PD before the start of the next regimen.Xx_NEWLINE_xXSubjects must be scheduled for surgery at Medical University of South Carolina (MUSC) no less than 5 days from the planned start of day 1 and no more than 56 days from the planned start of day 1Xx_NEWLINE_xXHistological confirmation of adenocarcinoma of the prostate, >= Gleason 6, clinical stage T1a-T2c and planned for radical prostatectomyXx_NEWLINE_xXMust not have received nor be planned for neoadjuvant chemotherapy prior to SABR or surgeryXx_NEWLINE_xXChemotherapy is planned for the patient in the neoadjuvant settingXx_NEWLINE_xXOngoing or planned administration of anti-cancer therapies other than nivolumabXx_NEWLINE_xXPrior experimental therapy within 4 weeks of planned start of this trialXx_NEWLINE_xXThe planned treatment regimen must be concurrent chemoradiation with carboplatin-paclitaxel followed by surgeryXx_NEWLINE_xXAt the time of study enrollment, patients must have at least 4 months of adjuvant trastuzumab plannedXx_NEWLINE_xXPrior radiation treatment less than 6 months from the planned start of reirradiation of any part of the intended treatment volumeXx_NEWLINE_xXPatients with MRI or clinical evidence of uncontrolled tumor mass effect are excluded; the assessment of mass effect should be made by the study chair(s) and study neurosurgeon prior to any planned CED treatmentXx_NEWLINE_xXHistopathologically proven adenocarcinoma, Gleason grade ? 7 of the prostate planned radical prostatectomy; appropriate for treatment with paclitaxel therapyXx_NEWLINE_xXDiagnosis of head and neck squamous cell carcinoma that is either biopsy proven or suspected based on history, physical, and or radiographic findings, and who are planned for definitive resection of the tumor without the use of neoadjuvant chemotherapy or radiation therapy at Thomas Jefferson University Hospital (TJUH) are eligible to participateXx_NEWLINE_xXNo known/planned active dental or jaw condition which requires oral surgery, including tooth extractionXx_NEWLINE_xXPatients have planned invasive dental procedures during the course of the studyXx_NEWLINE_xXNo planned palliative procedures for alleviation of bone pain such as radiation therapy or surgeryXx_NEWLINE_xXPrior radiotherapy that would result in overlap of radiation treatment fields with planned treatment for study cancer.Xx_NEWLINE_xXPatients in which hemithoracic radiation therapy is plannedXx_NEWLINE_xXPlanned to get local surgeryXx_NEWLINE_xXPlanned total, near-total or completion thyroidectomy requiring lifelong thyroid hormone replacementXx_NEWLINE_xXPlanned goal TSH suppression 0.1-0.5 mU/L for at least 18 weeks postoperativelyXx_NEWLINE_xXPlanned postoperative TSH goal different than 0.1-0.5 mU/LXx_NEWLINE_xXTumor size at least 5 mm with planned primary surgery at Mount SinaiXx_NEWLINE_xXThe parent study is closed or planned to be closed; andXx_NEWLINE_xXSubjects for whom use of a thrombolytic, either systemic or via catheter, is planned;Xx_NEWLINE_xXPatients who have been treated with chemotherapy or radiation within two weeks of planned study enrollment; this does not include hydroxyurea, which may be continued until start of conditioning therapy; ruxolitinib may be continued at principal investigator's discretion during conditioningXx_NEWLINE_xXPlanned use of maintenance or consolidative therapyXx_NEWLINE_xXDiagnosis of localized breast, uterine or cervical cancer that is either biopsy proven or suspected based on history, physical, and/or radiographic findings, and who are planned for definitive resection of the tumor without the use of neoadjuvant chemotherapy or radiation therapy at Thomas Jefferson University Hospital (TJUH) are eligible to participateXx_NEWLINE_xXSubjects with planned radiation therapy to a target lesion will be excludedXx_NEWLINE_xXPlanned neoadjuvant therapy with six cycles of combined pertuzumab, trastuzumab and chemotherapyXx_NEWLINE_xXPlanned neoadjuvant chemotherapy for breast cancer as determined by the judgment of the medical oncologistXx_NEWLINE_xXCurrent use of a prohibited medication or planned use of any forbidden medications during treatment with GSK3326595.Xx_NEWLINE_xXPrior experimental therapy within 30 days of planned start of this trialXx_NEWLINE_xXPlanned stereotactic body radiation therapy (SBRT) for the pulmonary metastasesXx_NEWLINE_xXActive infection or other serious underlying medical condition which would impair the ability of the patient to receive the planned treatmentXx_NEWLINE_xXThe patient has elective or planned major surgery to be performed during the course of the clinical trialXx_NEWLINE_xXA disposition to neoadjuvant chemotherapy with planned interval tumor reductive surgery after 3 complete cycles of treatmentXx_NEWLINE_xXPlanned chemotherapy with combination carboplatin and paclitaxel given intravenouslyXx_NEWLINE_xXPlanned pre-operative chemotherapy (patients with planned post-operative chemotherapy are eligible)Xx_NEWLINE_xXUse of chemotherapy within 4 weeks of the planned start of radiation therapyXx_NEWLINE_xXPlanned treatment with TTFields therapy.Xx_NEWLINE_xXPlanned resectional surgery for MPM (extrapleural pneumonectomy [EPP] or pleurectomy and decortication [P/D])Xx_NEWLINE_xXNo history of prior radiotherapy overlapping with high dose region of planned SABR courseXx_NEWLINE_xXFor patients with rHGG, the patient intends to undergo treatment with the Gliadel® wafer at the time of planned resection (ie, on-study surgery) or has received the Gliadel wafer < 30 days from the date of planned resection.Xx_NEWLINE_xXThe patient has elective or planned major surgery to be performed during the course of the clinical trialXx_NEWLINE_xXPre-operative or post-operative or planned radiation therapy for the current lung cancerXx_NEWLINE_xXBreast cancer, stage 0-3, deemed a surgically appropriate candidate for partial mastectomy with planned procedure for the sameXx_NEWLINE_xXFor subjects with ATRT only, subject must have seizures that are stable, not increasing in frequency or severity and controlled on current anti-seizure medication(s) for a minimum of 21 days prior to the planned first dose of tazemetostatXx_NEWLINE_xXCurrent or planned use of other investigational agents, or concurrent biological chemotherapy, or radiation therapy during the study treatment periodXx_NEWLINE_xXCurrent or planned use of agents that prolong or suspected to prolong QTcXx_NEWLINE_xXCurrent or planned use of other investigational agents, or concurrent biological, chemotherapy, or radiation therapy during the study treatment periodXx_NEWLINE_xXStudy treatment both planned and able to start within 7 days of randomisation.Xx_NEWLINE_xXCurrent, recent (within 4 weeks of the first infusion of this study), or planned participation in any other experimental drug studyXx_NEWLINE_xXPatients for whom busulfan/melphalan consolidation therapy following treatment with 131I-MIBG is plannedXx_NEWLINE_xXSystemic chemotherapy delivered or planned to be delivered within (+/-) 5 days of SRS re-irradiationXx_NEWLINE_xXCurrent use (or planned use during the treatment period) of other investigational agents, or biological, chemotherapy, radiation or other anti-tumor therapyXx_NEWLINE_xXCurrent, or recent (within 4 weeks of the first treatment of this study) cytotoxic chemotherapy (e.g. cisplatin, taxol) or experimental drug therapy, or planned participation in an experimental drug studyXx_NEWLINE_xXCurrent, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug studyXx_NEWLINE_xXThe time from the end last induction, re-induction, or consolidation regimen should be greater than or equal to 14 days from planned start of study treatment; Note: Chemotherapy given within 14 days of planned study enrollment for the purpose of controlling counts is permittedXx_NEWLINE_xXSerum bilirubin > 2.0 mg/dl (unless segmental infusion is planned)Xx_NEWLINE_xXPrior radiation therapy in the planned treatment fieldXx_NEWLINE_xXPrior or planned neoadjuvant systemic therapy for breast cancerXx_NEWLINE_xXPlanned stereotactic biopsy as standard of care (i.e., for confirmation of disease progression)Xx_NEWLINE_xXPatient can have prior SRS to lesions other than the one planned for neoadjuvant SRS and resectionXx_NEWLINE_xXBreast surgery (lumpectomy or mastectomy) is planned for at least 7 days from the day of enrollmentXx_NEWLINE_xXPatients with newly diagnosed brain metastases are eligible as long as they are not planned for WBRT upfrontXx_NEWLINE_xXPlanned concurrent WBRTXx_NEWLINE_xXSurgery or radiation planned within 8 weeks of starting therapyXx_NEWLINE_xXTemozolomide re-treatment is planned by the treating neuro-oncologistXx_NEWLINE_xXPlanned use of OptuneXx_NEWLINE_xXEXCLUSION CRITERIA FOR REGISTRATION: subjects receiving neoadjuvant chemotherapy for whom interval debulking surgery (assuming adequate response to therapy) is not plannedXx_NEWLINE_xXParticipants for whom chemotherapy or intraoperative or post-operative radiation therapy is planned as part of the overall primary tumor treatmentXx_NEWLINE_xXPlanned participation in any other experimental drug studyXx_NEWLINE_xXPrior radiation treatment less than 3 months from planned start of re-irradiation of any part of the intended treatment volumeXx_NEWLINE_xXNo planned systemic treatment is allowed within one week after treatmentXx_NEWLINE_xXUnplanned donor lymphocyte infusion (DLI) for residual or relapsed malignancy or mixed chimerism. DLI as part of the planned HCT protocol is allowed.Xx_NEWLINE_xXPlanned to receive either primary or post-operative CRTXx_NEWLINE_xXPlanned IMRT (Intensity-Modulated Radiotherapy)Xx_NEWLINE_xXPlanned administration of cisplatin administered weekly or tri-weekly during RTXx_NEWLINE_xXPlanned to receive concomitant single agent chemotherapy with cisplatin given either weekly or tri-weeklyXx_NEWLINE_xXPlanned neoadjuvant chemoRT treatment must conform to NCCN guidelines.Xx_NEWLINE_xXPatients with any serious underlying medical condition that would impair their ability to receive or tolerate the planned treatment.Xx_NEWLINE_xXPlanned treatment, or treatment with any investigational drug within 4 weeks prior to screening.Xx_NEWLINE_xXElective or planned major surgery to be performed during the course of the trialXx_NEWLINE_xXCD3+ cells ? 100/µl at day of planned experimental infusion after haploidentical HCTXx_NEWLINE_xXPlan to begin partial brain radiotherapy within 24-72 hours after beginning AQ4N, and within 35 days (5 weeks) of the surgery, or if surgery cannot be performed, the biopsy that confirms GBM diagnosis. Radiation therapy must be given by external beam to a partial brian field in daily fractions of 2.0 Gy, to a planned total dose to the tumor of 60.0 Gy over 6 weeks.Xx_NEWLINE_xXUse of Avastin in the preceding two weeks or planned use in the forthcoming two weeks and VEGF inhibitors within + 30 days of treatmentXx_NEWLINE_xXPatients with planned standard of care ASCT using melphalan 200 mg/m^2Xx_NEWLINE_xXStudy treatment both planned and able to start within 14 days of randomisationXx_NEWLINE_xXHas received a T-cell product within 6 weeks prior to planned infusion of genetically modified T cells.Xx_NEWLINE_xXPatients whose clinical biopsies are found to be insufficient for the planned translational studies must be willing to undergo a research biopsy.Xx_NEWLINE_xXPatient must state willingness to undergo pre- and post-treatment biopsies. According to the investigator’s judgement, the planned biopsies should not expose the patient to substantially increased risk of complicationsXx_NEWLINE_xXPatient is on any systemic corticosteroid therapy within one week before the planned date for first dose of treatment or on any other form of immuno-suppressive medicationXx_NEWLINE_xXPatients with a planned use of Novo-TTF (Optune) are ineligibleXx_NEWLINE_xXCompleted planned breast surgeries and any radiation therapy >= 30 days prior to randomizationXx_NEWLINE_xXPlanned invasive dental procedures during the course of studyXx_NEWLINE_xXGross total or partial tumor resection is not possible or not plannedXx_NEWLINE_xXPlanned standard treatment with pembrolizumabXx_NEWLINE_xXDMG biopsy/resection is planned for the clinical care of the patient independent of study participation by the treating pediatric neurosurgeon and neuro-oncologistXx_NEWLINE_xXPlanned radiation therapy after transplantXx_NEWLINE_xXAny cytotoxic treatments, such as neoadjuvant chemotherapy, planned before subsequent surgical procedureXx_NEWLINE_xXEGFR TKI treatment discontinued less than or equal to 30 days prior to planned\n             initiation of rociletinibXx_NEWLINE_xXNo intervening treatment between cessation of single agent EGFR TKI and planned\n             initiation of rociletinibXx_NEWLINE_xXPatients must have successfully completed therapy with sipuleucel-T within 3-7 days of planned CYT107 study drug treatmentXx_NEWLINE_xXCurrent or planned use of other investigational agents, or concurrent biological, chemotherapy, or radiation therapy during the study treatment periodXx_NEWLINE_xXCurrent or planned use of prohibited medsXx_NEWLINE_xXSystemic therapy with sorafenib or other systemic chemotherapeutic agent(s) less than 1 week prior to first planned DEB-TACEXx_NEWLINE_xXNo brain radiation therapy > 4 weeks before planned start of protocol treatmentXx_NEWLINE_xXNo chemotherapy for > 3 weeks before planned start of protocol treatmentXx_NEWLINE_xXPatients with a history of prior therapy with another investigational agent within 4 weeks of the first planned dose of PF-0444913Xx_NEWLINE_xXHistory of metastatic cancer diagnosed less than 2 years prior to the first planned dose of PF-0444913Xx_NEWLINE_xXPatients with multiple, ipsilateral pulmonary nodules (T3 or T4) are eligible if a definitive course of daily fractionated radiation therapy (RT) is plannedXx_NEWLINE_xXCurrent, recent (within 4 weeks of the first treatment of this study), or planned participation in an experimental drug study (prevention trials are permitted if the trial is not testing a novel experimental agent)Xx_NEWLINE_xXFOR COHORT A ONLY: high-dose chemotherapy and AHCT must be planned; post-transplant maintenance therapy will not be permittedXx_NEWLINE_xXAny acute, inter-current infection that may interfere with planned protocol treatment; participants with mycobacterium avium will not be excluded from study entry; chronic therapy with potentially myelosuppressive agents is allowed provided that entry hematologic criteria are metXx_NEWLINE_xXThe entire tumor volume must be included in a treatment field that limits the total spinal cord dose to 54 Gy (prior plus planned dose)Xx_NEWLINE_xXCancer for which intraperitoneal cytotoxic chemotherapy is plannedXx_NEWLINE_xXPatients must not have received prior WBRT (previous SRS/SRT done at least 4 weeks from the planned start of WBRT is acceptable); patients planned upfront to undergo SRS/SRT/fractionated boosts or neurosurgery after WBRT are not eligible; however, these treatments/procedures can be performed once the dose limiting toxicity (DLT) assessment has been completed, if felt clinically necessaryXx_NEWLINE_xXPlanned liver directed therapy or radiation therapyXx_NEWLINE_xXContraindications to the planned second line standard-of-care chemotherapy regimenXx_NEWLINE_xXPatients whose entry to the trial will cause unacceptable clinical delays in their planned managementXx_NEWLINE_xXPatients must be planned to receive whole pelvic radiotherapy to a total dose of 45 Gy or greaterXx_NEWLINE_xXMale subjects must refrain from donating sperm starting at the planned first dose of investigational product (IP) until 30 days following the last dose of IPXx_NEWLINE_xXPlanned treatment with other experimental drugs or any other non-hormonal anti-cancer therapy;Xx_NEWLINE_xXMonoclonal antibody therapy within 4 weeks prior to the planned start of study treatment.Xx_NEWLINE_xXChemotherapy within 21 days or at least 5 half-lives prior to the planned start of study treatment; radiation outside the thorax within 14 days prior to the planned start of study treatment or thoracic radiation; antibody based therapy or investigational therapy within 28 days prior to the planned start of study treatment.Xx_NEWLINE_xXUse or planned use of any medications that have a known risk or possible risk to prolong the QT intervalXx_NEWLINE_xXTreatment with other locoregional therapies (other than study treatment) has not been planned for the duration of the clinical study periodXx_NEWLINE_xXNo prior or scheduled Gliadel® wafer implant unless area of assessment and planned resection is outside the region previously implanted.Xx_NEWLINE_xXNo prior interstitial brachytherapy or stereotactic radiosurgery unless area of assessment and planned resection is outside the region previously treated.Xx_NEWLINE_xXThe trial is open only to women with primary endometrioid adenocarcinoma of the uterine corpus (all histologic grades and stages) who are planned and appropriate for primary surgical treatmentXx_NEWLINE_xXBreast surgery plannedXx_NEWLINE_xXhave an elective or a planned major surgery during the course of the trialXx_NEWLINE_xXVaccinated with any of the vaccines planned for administration in the trial within 8 weeks of starting treatment on the studyXx_NEWLINE_xXNo planned concomitant, non-protocol directed anti-cancer therapyXx_NEWLINE_xXPlanned resection of primary tumorXx_NEWLINE_xXSystemic therapy, if planned, must be adjuvant in nature and not be scheduled to begin for at least 4 weeks after completion of HG-PBIXx_NEWLINE_xXOngoing or planned administration of anti-cancer therapies other than those specified in this studyXx_NEWLINE_xXCurrent or planned use of systemic therapy for extracranial primary tumorXx_NEWLINE_xXChronic or planned acute alcohol use of 3 or more drinks per dayXx_NEWLINE_xXOther concurrent serious diseases that may interfere with planned treatment including severe pulmonary conditions/illnessXx_NEWLINE_xXAllogeneic transplant within 30 days prior to the planned start of treatment or subjects with active graft-vs-host disease with the exception of Grade 1 skin involvementXx_NEWLINE_xXPatients for whom concurrent Adriamycin or gemcitabine chemotherapy is planned, unless on a concurrent protocol (such as a COG sponsored protocol)Xx_NEWLINE_xXLaboratory values as follows at screening and within 7 days of planned first dose of therapy:Xx_NEWLINE_xXCurrent use of a prohibited medication or planned use of any forbidden medications during treatment with GSK2820151.Xx_NEWLINE_xXConcurrent or planned concurrent treatment with anticoagulants such as Coumadin or heparin, except to maintain patency of in dwelling cathetersXx_NEWLINE_xXCurrent or planned pregnancy within the next three months (females only)Xx_NEWLINE_xXNon-CNS progression of disease as assessed by the investigator/treating physician, for which a change in systemic therapy is planned OR achievement of stable or responsive non-CNS disease for which a holiday from the current systemic therapy is planned, as assessed by the investigator/treating physicianXx_NEWLINE_xXReduction mammoplasty if 3DCRT or proton APBI are plannedXx_NEWLINE_xXStudy treatment both planned and able to start within 7 days after randomisation.Xx_NEWLINE_xXOngoing or planned administration of anti-cancer therapies other than those specified in this studyXx_NEWLINE_xXCurrent, recent (within 4 weeks of the administration of this study agent), or planned participation in an experimental drug studyXx_NEWLINE_xXChemotherapy < 2 weeks prior to the first planned dose of study treatmentXx_NEWLINE_xXRadiation therapy planned to start =< 8 weeks after surgery and at least 7 days after the start of minocyclineXx_NEWLINE_xXPatients are eligible if an autologous transplant is planned within approximately 12 months from the time of collection of cellsXx_NEWLINE_xXPlanned surgical procedure that can impact the conduct of the studyXx_NEWLINE_xXPatients must have histologically squamous cell carcinoma of the head and neck and be planned for definitive radiation and chemotherapyXx_NEWLINE_xXPatient must be scheduled to undergo either a single or bilateral elective nipple-areola skin sparing mastectomy (NASSM) procedure with planned immediate reconstructionXx_NEWLINE_xXPatients planned invasive dental proceduresXx_NEWLINE_xXNo planned palliative procedures for alleviation of bone pain such as radiation therapy or surgeryXx_NEWLINE_xXPatients must have completed all planned/elective surgeries > 4 weeks and must have recovered from surgery before registration; participants should try to avoid any additional elective surgeries during the study period; particular instances may be discussed with Protocol Chair/designeeXx_NEWLINE_xXIntercurrent illness likely to prevent protocol therapy or conventional planned therapyXx_NEWLINE_xXSubject progressed during or within 3 months of completion of a planned course of first-line therapy with Rituximab-Cyclophosphamide, Hydroxydaunomycin, Vincristine (Oncovin), Prednisone (R-CHOP) or an equivalent regimen;Xx_NEWLINE_xXParticipants who relapsed from at least 1 previous treatment AND additionally were refractory to at least 1 previous treatment. For the purposes of this study, refractory disease was defined as disease progression on treatment or progression within 60 days after the last dose of a given therapy. A line of therapy was defined as 1 or more cycles of a planned treatment program. This may have consisted of 1 or more planned cycles of single-agent therapy or combination therapy, as well as a sequence of treatments administered in a planned manner. For example, a planned treatment approach of induction therapy followed by autologous stem cell transplantation, followed by maintenance was considered 1 line of therapy. Autologous and allogenic transplants were permitted.Xx_NEWLINE_xXSubjects who have received live virus vaccination within the 4 weeks prior to planned initiation of study treatmentXx_NEWLINE_xXCurrent, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug studyXx_NEWLINE_xXPatients must have no evidence of active graft-versus-host disease and must be on a stable immunosuppressive regimen (or no immunosuppressive medications) without a change in drugs dosage in the 4 weeks prior to the planned CD8+ memory T cell infusionXx_NEWLINE_xXPatients to be scheduled for a planned tumor debulkingXx_NEWLINE_xXCurrent, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer studyXx_NEWLINE_xXCurrent, recent (within 2 weeks of enrollment of this study), or planned participation in an experimental drug studyXx_NEWLINE_xXRadiation therapy to brain for DIPG that was completed at least 10 months prior to planned reirradiationXx_NEWLINE_xXAt least one measurable site of disease (>= 1.5 cm) outside of the planned palliative radiation therapy fieldXx_NEWLINE_xXPlanned cytotoxic chemotherapy during the SRS or WBRTXx_NEWLINE_xXWomen with planned treatment of primary definitive chemoradiation therapyXx_NEWLINE_xXWomen with planned treatment of radiotherapy only (without chemotherapy)Xx_NEWLINE_xXWomen with planned treatment of palliative radiotherapyXx_NEWLINE_xXPatients with any serious underlying medical condition that would impair their ability to receive or tolerate the planned treatmentXx_NEWLINE_xXConcurrent or planned radiation, hormonal, chemotherapeutic, experimental or targeted biologic therapyXx_NEWLINE_xXSurgery must be planned to be performed by a pre-approved, study-specific credentialed surgeon; the registering physician MUST be the pre-approved, credentialed surgeon intended to perform the assigned procedureXx_NEWLINE_xXChemotherapy given on the day of the planned radiotherapy treatmentXx_NEWLINE_xXIf chemotherapy is planned, it must begin no earlier than two weeks following completion of radiation therapyXx_NEWLINE_xXCurrent, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer studyXx_NEWLINE_xXOngoing or planned systemic anti-cancer therapy or radiation therapyXx_NEWLINE_xXPlanned first-line chemotherapy contains a proteasome-inhibiting agent administered weeklyXx_NEWLINE_xXHave a planned low circular stapled or transanally hand sewn anastomosis ?10 cm from the anal verge.Xx_NEWLINE_xXChange in chemotherapy agent is planned 7 days before or after enrollment (change in dose(s) permitted),Xx_NEWLINE_xXMajor elective surgery to the spine in same region as the index vertebra(e) is planned within 1 month following the ablation and cement procedure,Xx_NEWLINE_xXElective or a planned major surgery while on study treatmentXx_NEWLINE_xXPlanned invasive dental procedure for the course of the studyXx_NEWLINE_xXChemotherapy or investigational antineoplastic drug within 1 month of planned initiation of vaccine therapyXx_NEWLINE_xXCurrent use (or planned use during the treatment period) of other investigational agents, or biological, chemotherapy, radiation or other anti-tumor therapyXx_NEWLINE_xXPlanned to be treated by active surveillanceXx_NEWLINE_xXCurrent, recent (within 2 weeks of enrollment of this study), or planned participation in an experimental drug studyXx_NEWLINE_xXThe patient will need to be available for evaluation within 72 hours of symptoms of GVHD, occurring within 60 days of the planned donor lymphocyte infusionXx_NEWLINE_xXPlanned use of any treatment for PTCL during the course of the study.Xx_NEWLINE_xXHas, at the planned initiation of study drug, an uncontrolled infection.Xx_NEWLINE_xXParticipant who received a prior treatment intended for antitumor effect (medication, surgery, radiotherapy, etc.) within 4 weeks prior to the planned first day of study drug dosing (or participant who received mitomycin C or Nitrosourea within 6 weeks prior to the planned first day of study drug dosing).Xx_NEWLINE_xXParticipant who were treated with other investigational drug or medical device within 4 weeks prior to the planned first day of study drug dosing.Xx_NEWLINE_xXMale subjects with pregnant or lactating partners or partners who plan to become pregnant while on study or within 6 months after the planned administration of the last dose of study drugXx_NEWLINE_xXPrior neoadjuvant chemotherapy or biologic therapy for current clinically or biopsy-proven node positive breast cancer within 4 weeks before the planned surgery.Xx_NEWLINE_xXPatient has an infection and has had a body temperature of > 38.3?C within 48 hours prior to planned first dose of study drug.Xx_NEWLINE_xXsurgery, radiation, or immunosuppressants within 28 days prior to planned first dose of study drug,Xx_NEWLINE_xXPlanned enucleation or brachytherapy of the study eye due to uveal melanomaXx_NEWLINE_xXContraindication to receive vincristine or any planned protocol-specified chemotherapyXx_NEWLINE_xXAnti-cancer chemotherapy or biologic therapy if administered prior to the first planned dose of BBI608/placebo within period of time equivalent to the usual cycle length of the regimen. An exception is made for oral fluoropyrimidines (e.g. capecitabine, S-1), where a minimum of 10 days since last dose must be observed prior to the first planned dose of BBI608/placebo.Radiotherapy, immunotherapy, or investigational agents within four weeks of first planned dose of BBI608/placebo, with the exception of a single dose of radiation up to 8 Gray (equal to 800 RAD) with palliative intent for pain control up to 14 days before randomization.Xx_NEWLINE_xXMacroscopic complete resection of the primary tumor must be plannedXx_NEWLINE_xXBiopsy-proven non-metastatic squamous cell carcinoma of the mouth or oropharynx and is planned to receive a standard course of concomitant CRT.Xx_NEWLINE_xXPlanned to receive standard cisplatin chemotherapy administered either weekly or every third week.Xx_NEWLINE_xXHas the subject received Avastin® (bevacizumab) for this recurrence/progression, or within the 4 weeks prior to planned Visit 1?Xx_NEWLINE_xXPlanned biopsy or resection of recurrent tumor for therapeutic and/or diagnostic purpose, and with adequate bone marrow, hepatic, cardiac, and renal function to undergo this planned procedureXx_NEWLINE_xXPlanned to receive 4 to 6 cycles of pemetrexed or gemcitabine in combination with cisplatin or carboplatin • For subjects to receive pemetrexed, planned to receive vitamin B12 and folate per pemetrexed approved labelingXx_NEWLINE_xXPlanned to receive bevacizumabXx_NEWLINE_xXPlanned invasive dental procedures for the course of the study.Xx_NEWLINE_xXPlanned initiation, termination, or dose alteration of hydroxyurea during the studyXx_NEWLINE_xXOccurrence of major intraoperative complications that require resuscitation or deviation from the planned surgical procedure.Xx_NEWLINE_xXParticipation in a study of an investigational drug within 4 weeks prior to the planned first day of study drug administrationXx_NEWLINE_xXTreatment with molecularly targeted agents within the past 3 weeks prior to planned first study drug administration. Patients who were receiving standard chemotherapy or experimental therapies must wait 4 weeks from their last dose prior to the planned first study drug administration. Patients treated with nitrosoureas or mitomycin C must wait 6 weeks from their last dose prior to the planned first study drug administration.Xx_NEWLINE_xXHerbal supplements are prohibited 1 week prior to the planned first study drug administration, during the clinical study, and up to the time that the patient is discharged from the studyXx_NEWLINE_xXPlanned palliative procedures for alleviation of bone pain such as radiation therapy or surgeryXx_NEWLINE_xXPatients must have had endocrine therapy initiated or planned for >= 5 years; endocrine therapy can be given concurrently or following RTXx_NEWLINE_xXCurrent or planned glucocorticoid therapy, with the following exceptions:Xx_NEWLINE_xXRecent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants)Xx_NEWLINE_xXHas an elective or planned major surgery to be performed during the course of the trialXx_NEWLINE_xXElective or a planned major surgeryXx_NEWLINE_xXChemotherapy within 2 weeks of first planned fraction of SBRTXx_NEWLINE_xXPlanned invasive dental procedure for the course of the studyXx_NEWLINE_xXPlanned administration of alemtuzumab (Campath-1H) or other investigational agents as alternative agent for GVHD prophylaxisXx_NEWLINE_xXPlanned elective radical prostatectomy with bilateral nerve sparing technique that can include high or low fasciaXx_NEWLINE_xXHigh-risk cancer planned for neoadjuvant therapy, full or partial excision of one or both neurovascular bundlesXx_NEWLINE_xXHave surgery planned within 3 months of consent; patients who have previously received surgery are eligibleXx_NEWLINE_xXPlanned use of cytotoxic chemotherapy during radiation (only adjuvant temozolomide therapy will be used on this protocol)Xx_NEWLINE_xXSarcomas where radiation is not planned preoperativelyXx_NEWLINE_xXFor stage I-III disease, patients should be 2-24 months post-completion of surgery, radiation therapy and/or chemotherapy with no further planned treatment during the 12-week study and no evidence of diseaseXx_NEWLINE_xXPatient is currently receiving or planned to receive concurrent total parenteral nutrition and/or metoclopramideXx_NEWLINE_xXBeginning a new course of chemotherapy and/or immunotherapy (with a side effect profile that includes the symptoms monitored by SCH) that is planned for a minimum of three cyclesXx_NEWLINE_xXPlanned chemotherapy during radiosurgeryXx_NEWLINE_xXPlanned administration of bedside LR PLT transfusion(s)Xx_NEWLINE_xXPatients for whom complete cavity shaving is planned (sites where this is the routine practice of the investigator will also be excluded from participation in the study)Xx_NEWLINE_xXPlanned treatment with castration therapy (gonadotropin-releasing hormone [GnRH] agonist/antagonist) for >= 8 monthsXx_NEWLINE_xXDiagnosis of stage II-III colon or rectal cancer planned for treatment with adjuvant chemotherapy scheduled as part of standard treatmentXx_NEWLINE_xXPrior and/or planned concomitant medical therapy during the study period (through day 360 post-HCT) with other bisphosphonates, denosumab, or teriparatideXx_NEWLINE_xXPlanned administration of an investigational study drug or agent that either can interact with pamidronate or have an independent effect on bone mineral density within the 4 weeks prior to randomization (day 90) or planned use during study participation (day 90 through day 360)Xx_NEWLINE_xXPlanned use of post-HCT cyclophosphamide for GVHD prophylaxisXx_NEWLINE_xXAnticipated planned donor lymphocyte infusion in the first 3 months post-SCTXx_NEWLINE_xXINCLUSION CRITERIA:\n\n          1. Subjects must be ? 18 years old and have a life expectancy ? 12 weeks\n\n          2. Histologically proven, primary (de novo) GB that has recurred or progressed (first or\n             second recurrence, including this recurrence)\n\n          3. Confirmation that archived tissue is available from first diagnosis of GB for\n             biomarker analysis\n\n          4. Recurrent tumor must be supratentorial, contrast-enhancing GB no smaller than 1 cm x 1\n             cm (largest perpendicular dimensions) and no larger than 4 cm maximum in a single\n             direction based on MRI taken within 14 days prior to catheter placement\n\n          5. Karnofsky Performance Score (KPS) ? 70\n\n          6. Subjects must be able and willing to undergo multiple brain MRI examinations\n\n          7. Subjects must be able and willing to comply with all study procedures\n\n          8. Any related toxicities following discontinuation of prior GB therapies must have\n             resolved to CTCAE Grade 1 or lower prior to inclusion in this study\n\n        EXCLUSION CRITERIA:\n\n          1. Prior treatment with cytotoxic chemotherapy\n\n               1. Temozolomide (standard induction and / or maintenance dosing) within the past 4\n                  weeks prior to planned infusion\n\n               2. \Metronomic\ Temozolomide (low-dose, continuous administration) within the past 7\n                  days prior to planned infusion\n\n               3. Nitrosoureas within the past 6 weeks prior to planned infusion\n\n               4. Treatment with any other cytotoxic agent within the past 4 weeks prior to planned\n                  infusion\n\n          2. Prior investigational treatment within the past 4 weeks or prior immunotherapy or\n             antibody therapy within the past 4 weeks prior to planned infusion\n\n          3. Prior treatment with bevacizumab (Avastin) or other vascular-endothelial growth factor\n             (VEGF) inhibitors or VEGF-receptor signaling inhibitors within the past 4 weeks prior\n             to planned infusion\n\n          4. Prior therapy that included interstitial brachytherapy or Gliadel® Wafers (carmustine\n             implants) within the past 12 weeks prior to planned infusion\n\n          5. Prior surgery (including stereotactic radiosurgery and biopsy procedures) within the\n             past 4 weeks prior to planned infusion\n\n          6. Ongoing Optune© therapy within 5 days of planned infusion\n\n          7. Secondary GB (i.e., GB that progressed from low-grade diffuse astrocytoma or AA)\n\n          8. Known mutation in either the isocitrate dehydrogenase 1 (IDH1) or the IDH2 gene.\n\n          9. Tumor in the brainstem (not including fluid-attenuated inversion recovery [FLAIR]\n             changes), an infratentorial tumor, diagnosis of gliomatosis cerebri (highly\n             infiltrative T2 hyperintense tumor with ill-defined margins encompassing at least\n             three lobes of the brain.\n\n         10. Tumor with a mass effect (e.g. 1-2 cm midline shift)\n\n         11. Subjects with tumors for which the preponderance of tissue is not of the type in which\n             convection would be possible (e.g. preponderance of cystic component)\n\n         12. Tumor with geometric features that make them difficult to adequately cover the tumor\n             volume with infusate by using CED catheters\n\n         13. Clinical symptoms that are thought by the Investigator to be caused by uncontrolled\n             increased intracranial pressure, hemorrhage, or edema of the brain\n\n         14. Any condition that precludes the administration of anesthesia\n\n         15. Known to be human immunodeficiency virus positive\n\n         16. Concurrent or a history of any significant medical illnesses that in the\n             Investigator's opinion cannot be adequately controlled with appropriate therapy or\n             would compromise the subject's ability to tolerate the study drug therapy and/or put\n             the subject at additional risk or interfere with the interpretation of the results of\n             this trial\n\n         17. Known history of allergy to gadolinium contrast agents\n\n         18. Presence of another type of malignancy requiring treatment within < 3 years prior to\n             the screening visit, except for adequately treated carcinoma in-situ of the cervix,\n             prostate cancer not actively treated, and basal or squamous cell carcinoma of the skinXx_NEWLINE_xXReceipt of radiation to the abdomen for any reason during the planned 10-day treatment timeXx_NEWLINE_xXRadiosensitive histology with planned RT dose less than 50 gray.Xx_NEWLINE_xXNo planned reconstructive surgery with flap repair during trial and follow-up periodXx_NEWLINE_xXNo surgery planned in the next 6 monthsXx_NEWLINE_xXUndergoing bilateral mastectomy reconstruction with tissue expanders (ipsilateral therapeutic/contralateral prophylactic) planned to be exchanged for breast implantsXx_NEWLINE_xXSubjects must have prostate cancer being treated via radical prostatectomy by a single surgeon (primary investigator) with planned intraoperative nerve sparing.Xx_NEWLINE_xXSubjects who have concurrent illness requiring systemic corticosteroid use other than the planned dexamethasone during conditioning therapyXx_NEWLINE_xXPlanned for bilateral axillary surgeryXx_NEWLINE_xXPatient is planned to receive hypofractionated palliative radiation =< 10 fractionsXx_NEWLINE_xXPatient is planned to receive interventional procedures (i.e. surgery) that may affect study outcomesXx_NEWLINE_xXWomen diagnosed with breast cancer stages 0-III within 18 months after completion of all planned surgery, radiation and or chemotherapy treatmentsXx_NEWLINE_xXTreatment with antithymocyte globulin within 28 days of planned infusion of virus – specific, antigen selected T cellsXx_NEWLINE_xXTreatment with virus – specific T cells within 6 weeks (42 days) of planned infusionXx_NEWLINE_xXGIST patients with iron deficiency anemia (IDA) planned to start or are receiving systemic therapy with tyrosine kinase inhibitors (TKIs)Xx_NEWLINE_xXPlanned neoadjuvant systemic therapyXx_NEWLINE_xXNo surgery planned in the next 6 monthsXx_NEWLINE_xXPrevious radiotherapy or palliative surgery to the painful site that is planned for treatmentXx_NEWLINE_xXSpinal cord or cauda equine compression/effacement in vertebral metastases with neurological symptoms other than just pain for the lesion that is planned for treatmentXx_NEWLINE_xXPlanned non-myelosuppressive chemotherapy regimenXx_NEWLINE_xXPlanned primary or adjuvant chemoradiation therapyXx_NEWLINE_xXPrimary treatment is active surveillance (AS) with planned annual surveillance biopsiesXx_NEWLINE_xXPatients with a planned exploration with biopsies (no organs removed) will be excluded from the studyXx_NEWLINE_xXPlanned surgeries or radiation treatment within 10 weeks following study inclusionXx_NEWLINE_xXSubjects with significant concurrent medical complications that in the judgment of the principal investigator(s) could affect the patient's ability to complete the planned trial; there are no therapy restrictions or restrictions regarding the use of other investigational agentsXx_NEWLINE_xXBe scheduled for planned cancer treatment (e.g. chemotherapy or biologics such as Herceptin)Xx_NEWLINE_xXWillingness to be followed for the planned duration of the trial (2 years)Xx_NEWLINE_xXPlanned treatment with R-CHOP chemotherapyXx_NEWLINE_xXPlanned HCT with minimal to no-T cell depletion of graftXx_NEWLINE_xXHas planned external beam radiotherapy (+/- chemotherapy) for 6-7 weeksXx_NEWLINE_xXKnown or suspected gynecologic or other abdominal malignancy (such as colorectal, liver, pancreatic, kidney and stomach) for which laparotomy is plannedXx_NEWLINE_xXPlanned HCT with no ex-vivo T cell depletion of graft; conditioning and immunosuppressive regimens according to institutional guidelines are permittedXx_NEWLINE_xXPlanned HCT with minimal to no-T cell depletion of graftXx_NEWLINE_xXPlanned less than two week hospitalizationXx_NEWLINE_xXPlanned concurrent chemotherapy or antitumoral agent during PCIXx_NEWLINE_xXCurrent, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer studyXx_NEWLINE_xXHave surgery planned within 3 months of consent; patients who have previously received surgery are eligibleXx_NEWLINE_xXPlanned participation in the Gynecologic Enhanced Recovery PathwayXx_NEWLINE_xXCurrent or planned use of cyclosporine, anticoagulants, insulin, oral or injectable vitamin D doses over 4,000 IU/day, or tamoxifenXx_NEWLINE_xXTreatment plan to receive a continuous course of IMRT delivered as single daily fractions of 2.0 to 2.2 Gy with a cumulative radiation dose between 60 Gy and 72 Gy. Planned radiation treatment fields must include at least two oral sites (buccal mucosa, floor of mouth, tongue, soft palate) that are each planned to receive a total of > 50 Gy. Patients who have had prior surgery are eligible, provided they have fully recovered from surgery, and patients who may have surgery in the future are eligible.Xx_NEWLINE_xXNo planned ostomy creation at time of enrollmentXx_NEWLINE_xXPlanned treatment for stages I – III cancer at VICC or at MMC (patient)Xx_NEWLINE_xXCurrent diagnosis of a gastrointestinal, abdominal, or pelvic cancer for which the use of continuous definitive or adjuvant external-beam radiation therapy (RT) to the abdomen or pelvis to a minimum dose of 4500 cGy is plannedXx_NEWLINE_xXPlanned continuous antibiotic treatment during RTXx_NEWLINE_xXPlanned surgery anticipated during the intervention periodXx_NEWLINE_xXPlanned use of prophylactic donor lymphocyte infusion (DLI) therapyXx_NEWLINE_xXCurrent or planned use of methoxyflurane, oral contraceptives, isotretinoin, penicillin, or ergot alkaloidsXx_NEWLINE_xXScheduled for intended pancreatectomy, > 4 weeks until planned resectionXx_NEWLINE_xXAbnormal global longitudinal strain (< 19%, or a % decrease of >= 11% from baseline) prior to initiation of planned anti-HER2 therapyXx_NEWLINE_xXPlanned fractionated external beam radiotherapy to be delivered by opposing, tangential beams to 50.4 Gy in 28 fractions with a planned photon or electron boost of 10 Gy in 5 fractions (for a total of 33 fractions)Xx_NEWLINE_xXPlanned relocation which would make follow-up visits impossible during the course of the studyXx_NEWLINE_xXNormal ipsilateral fibula without planned fibular osteotomy at time of surgeryXx_NEWLINE_xXA disposition to neoadjuvant chemotherapy with planned interval tumor reductive surgery after 4 complete cycles of treatmentXx_NEWLINE_xXPlanned dose-dense chemotherapy with combination carboplatin and paclitaxel given intravenouslyXx_NEWLINE_xXPlanned use of an epidural for surgery for post-operative pain reliefXx_NEWLINE_xXThe planned procedure is a clean-contaminated (class II) case (includes gastric, small bowel, and colorectal resections, as well as bile or pancreatic duct transections)Xx_NEWLINE_xXPlanned radiation therapy or surgery to the bone (does not include procedures performed before randomization)Xx_NEWLINE_xXPlanned invasive dental proceduresXx_NEWLINE_xXNo planned surgery anticipated in the 3-month intervention periodXx_NEWLINE_xXSubjects who have previously received or have planned Total Body Irradiation (TBI)Xx_NEWLINE_xXPatients with planned laparoscopic PDXx_NEWLINE_xXPlanned stereotactic body radiation therapy (SBRT)Xx_NEWLINE_xXCurrent active treatment with chemotherapy, radiation or surgery in the past 3 months or planned treatment during this study protocol period; hormonal therapy is allowedXx_NEWLINE_xXPlanned or actual changes in type of medications that could affect symptoms related to CIPN; new medications for the treatment of CIPN are not allowed during the study; Note: subjects need to be on stable doses for 4 weeksXx_NEWLINE_xXHave a plan to receive a continuous course of conventional external beam irradiation delivered by intensity-modulated radiotherapy (IMRT) as single daily fractions of 2.0 Gy to 2.2 Gy with a cumulative radiation dose ?55 Gy and ?72 Gy. Planned radiation treatment fields must include at least two oral sites (buccal mucosa, floor of mouth, ventral/lateral tongue, soft palate). [Note: the independent RTQA consultant must confirm that the planned radiation treatment meets the protocol criteria]Xx_NEWLINE_xXPlanned use of cisplatin as induction chemotherapy.Xx_NEWLINE_xXSurgical intervention is planned primary mechanism of local controlXx_NEWLINE_xXAt least 1 night of planned inpatient stayXx_NEWLINE_xXPlanned total laryngectomy at Barnes Jewish Hospital (BJH)Xx_NEWLINE_xXPlanned outpatient surgeryXx_NEWLINE_xXPlanned greater than one night admission to the intensive care unit (ICU)Xx_NEWLINE_xXMacroscopic resection of the tumor via TORS must be planned with curative intentXx_NEWLINE_xXWomen who are being seen at the Women's Health Center by the Gynecologic Oncology group at the University of Minnesota if planned surgery includes an exploratory laparotomyXx_NEWLINE_xXPatient is expected to receive 2 weekly doses of vincristine as outlined by the Total XVI or “as per TOTXVI” protocol while on study drug (i.e. no known dosage reductions or planned missed doses)Xx_NEWLINE_xXPatient receiving any investigational drug for hyperuricemia within 30 days of planned first treatment with rasburicaseXx_NEWLINE_xXSubjects who are planned to receive > 2 mg flat dose of vinca alkaloidsXx_NEWLINE_xXPatients who have been treated with chemotherapy or radiation within two weeks of planned study enrollment; this does not include hydroxyurea or ruxolitinib, which may be continued until start of conditioning therapyXx_NEWLINE_xXPlanned cisplatin treatment restricted to the following treatment course criteria:\r\n* Dose: > 50 mg/m^2\r\n* Frequency: every (q)3-q4 weeks\r\n* Cycles: 7 maximumXx_NEWLINE_xXCurrent active treatment with chemotherapy, radiation or surgery in the past 3 months or planned treatment during this study protocol period; hormonal therapy is allowedXx_NEWLINE_xXPlanned course of definitive or post-operative radiotherapy (RT) to a total dose of ? 60 Gy using 1.8 to 2.0 Gy per fractionXx_NEWLINE_xXPlanned concurrent administration of cisplatin chemotherapy (either 100 mg/m^2 every 3 weeks or 30-40 mg/m^2 every week)Xx_NEWLINE_xXSplit-course RT is plannedXx_NEWLINE_xXCurrent diagnosis of cancer that supports the use of continuous definitive or adjuvant external-beam RT to the pelvis to a minimum dose of 4500 cGy with the following parameters:\r\n* The pelvis must be encompassed by the planned RT fields; the superior border may not lie inferior to the most inferior aspect of the sacroiliac joints; portions of the rectum may have special blocking, depending upon disease site\r\n* The total prescription dose must lie between 4500-5350 cGy (inclusive); a boost to primary tumor or tumor bed may be planned\r\n* Planned treatment is to be given 4-5 times per week on a one–treatment-per-day basis; the daily prescribed dose must lie between 170-210 cGy (inclusive) per dayXx_NEWLINE_xXPlanned use of leucovorin (because of the risk of secretory diarrhea)Xx_NEWLINE_xXSplit-course RT is plannedXx_NEWLINE_xXPlanned continuous antibiotic treatment during RTXx_NEWLINE_xXCurrent or planned use of other agents for treating hot flashesXx_NEWLINE_xXCurrent or planned use of any type of antidepressantsXx_NEWLINE_xXNot planned for surgical interventionXx_NEWLINE_xXParticipants with thyroid carcinoma or thyroid disease for whom systemic radioactive iodine therapy is part of planned diagnostic work-up or treatment within 2 months following the contrast mammogram study.Xx_NEWLINE_xXEXCLUSION - PATIENT: Breast biopsy or surgical intervention planned before the test RSI-MRI in this studyXx_NEWLINE_xXParticipants with thyroid carcinoma or thyroid disease for whom systemic radioactive iodine therapy is part of planned diagnostic work-up or treatment within 2 months following the contrast mammogram studyXx_NEWLINE_xXThe patient’s planned cancer management is radiation to the liver with or without chemotherapyXx_NEWLINE_xXFor Arm 1 patients, the time from the TRUS prostate biopsy to the planned first study PET scan must be >= 1 month; for patients who have undergone prior prostate mapping biopsy, the time from the mapping biopsy to the planned first study PET scan must be >= 2 monthsXx_NEWLINE_xXCytotoxic chemotherapy within 4 weeks of first planned study PET/CT scanXx_NEWLINE_xXFilgrastim (G-CSF) therapy within 10 days of the first planned research PET/CT scanXx_NEWLINE_xXPlanned 3-4 drug systemic induction chemotherapy with a corticosteroid, vincristine and a single dose or multiple doses of asparaginase, with or without daunorubicinXx_NEWLINE_xXPlanned myeloablative conditioning regimenXx_NEWLINE_xXWomen who are planned to receive neoadjuvant therapyXx_NEWLINE_xXNo recent or planned immunotherapyXx_NEWLINE_xXRECIPIENT: Planned medications from the time of HCT to day 70 post?HCTXx_NEWLINE_xXNo future cancer therapy plannedXx_NEWLINE_xXParticipants need to have had a mammogram within 180 days of day 0 (normal/benign bi-rads 1 or 2) with no suspicion of a mass and no further routine breast imaging planned during the course of the study (4 weeks)Xx_NEWLINE_xXCurrent or planned use of anticoagulants other than aspirin or non-steroidal anti-inflammatory agentsXx_NEWLINE_xXPlanned allogeneic HCT using fludarabine phosphate (FLU)/melphalan hydrochloride (MEL) or FLU/busulfan (BU) conditioningXx_NEWLINE_xXPatient who has been started on systemic corticosteroid therapy within 72 h prior to study drug administration or is planned to receive a corticosteroid as part of the chemotherapy regimenXx_NEWLINE_xXUse of any drugs or substances known to be CYP3A4 substrates with narrow therapeutic range within 1 week prior to Day 1, or planned to be used during the overall study period.Xx_NEWLINE_xXUse of any drugs or substances known to be inducers of CYP3A4 enzymes within 4 weeks prior to Day 1 or planned to be used during the overall study period.Xx_NEWLINE_xXOngoing radiation induced diarrhea or constipation or planned radiotherapy to the abdomen or pelvis while on studyXx_NEWLINE_xXThe patient is a candidate for surgical resection, with no planned neoadjuvant chemotherapy, and there is a planned surgery for the primary colorectal cancerXx_NEWLINE_xXPatients who are treated for a medical condition (such as ulcerative colitis) with chronic steroids during the 2 years prior to planned mastectomy surgeryXx_NEWLINE_xXPrior or planned bariatric surgeryXx_NEWLINE_xXCurrently enrolled or planned to enroll in weight loss programXx_NEWLINE_xXAt randomization, their planned course of antibacterial drug treatment for CDI is longer than 21 daysXx_NEWLINE_xXCurrent or planned pregnancyXx_NEWLINE_xXNo planned prostate biopsies during the intervention until after the post-intervention biopsyXx_NEWLINE_xXMen on stable doses of 5-alpha reductase inhibitors are eligible as long as there is no planned dose change while on studyXx_NEWLINE_xXPlanned to undergo allo-HSCTXx_NEWLINE_xXCurrent or planned pregnancyXx_NEWLINE_xXHas evidence of cancer at the time of enrolment, or has surveillance tests planned within 21 weeks after enrollmentXx_NEWLINE_xXPatient planned to receive altered fractionation radiotherapy or multiple fractions per dayXx_NEWLINE_xXIndividuals with a history of bariatric surgery or planned bariatric surgery within 2 yearsXx_NEWLINE_xXPregnancy in the last 6 months/planned within the next 2 years or currently lactatingXx_NEWLINE_xXPlanned reconstructive surgery with flap repair during study periodXx_NEWLINE_xXCurrent or planned use of immunomodulators including: infliximab, 6?MP (mercaptopurine), methotrexate, cyclosporine, or other immunomodulatory drugsXx_NEWLINE_xXNo less than 3 weeks between the last dose of the prior treatment regimen (injectable HMA (HYPOMETHYLATING AGENT) - azacitidine for injection or decitabine) and the planned date of first dose of IP (IINVESTIGATIONAL PRODUCT).Xx_NEWLINE_xXPatient should be eligible for both spinal/epidural anesthesia (planned procedure), and general anesthesia (in case of complication, requiring intervention).Xx_NEWLINE_xXPatients with lesions of Gleason 7 or greater outside the planned treatment area.Xx_NEWLINE_xXPlanned partial breast radiationXx_NEWLINE_xXPlanned use of ex vivo or in vivo T-cell depletionXx_NEWLINE_xXSubject is planned to undergo either of the following:Xx_NEWLINE_xXMammogram within no more than 6 months prior to the date of informed consent (normal/benign Breast Imaging-Reporting and Data System [BI-RADS] 1 or 2) and no further routine breast imaging planned during the course of the study (12 weeks DHA/placebo)Xx_NEWLINE_xXCurrent or planned pregnancy within the next three months (females only)Xx_NEWLINE_xXPlanned reduced intensity conditioning regimen (see eligible regimens in Table 2.4a)Xx_NEWLINE_xXPlanned use of anti-thymocyte globulin (ATG) or alemtuzumab in conditioning regimen.Xx_NEWLINE_xXPlanned post-transplant therapy, including use of tyrosine-kinase inhibitors (TKI).Xx_NEWLINE_xXplanned treatment course to include Cisplatin and radiation therapy, cumulative prescription dose between 50-70 GyXx_NEWLINE_xXPrevious vaccination against HPV or planned administration of another HPV vaccine during the study other than that foreseen in the protocol.Xx_NEWLINE_xXAdministration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.Xx_NEWLINE_xXPatient must not have planned treatment with immunotherapies (vaccines, checkpoint inhibitors, T-cells); if the patient’s most recent recurrence occurs while on immunotherapy, this must be judged as true recurrence using Immunotherapy Response Assessment in Neuro-Oncology (iRANO) criteriaXx_NEWLINE_xXInsufficient leukemia or MDS specimen available for profiling from diagnosis or recurrence; or bone marrow evaluations NOT planned for clinical care; or peripheral blast percentage < 20% AND clinical blood draw not planned; or patient sample did NOT already complete rapid heme panel leukemia profiling clinicallyXx_NEWLINE_xXSurgery/biopsy planned as part of clinical care that is anticipated to yield sufficient material to meet the minimum requirements for profiling; ORXx_NEWLINE_xXScheduled or planned radical prostatectomy with PLND. Cohort B Only: [Enrollment is complete; No longer recruiting subjects]Xx_NEWLINE_xXScheduled or planned percutaneous biopsy of at least one amenable lesion.Xx_NEWLINE_xXPrior chemotherapy completed < 7 days prior to planned study entryXx_NEWLINE_xXPrior RT is allowed and must have been completed more than 7 days before planned study entry\r\n* Note: For re-irradiation cases, standard departmental guidelines should be followed so as to not exceed normal tissueXx_NEWLINE_xXPlanned WBRT based on number (>= 3 lesions) and/or size (>= 1 cm) of brain metastasesXx_NEWLINE_xXSurgery (mastectomy or BCT) planned within 60 days of the MRIXx_NEWLINE_xXFor cohort A, only patients with metastatic cancer to the brain for whom their treating physician has planned to give immunotherapy as monotherapy are eligible for this study; this can be in the setting of a clinical trial or notXx_NEWLINE_xXFor cohort B, only patients with GBM for whom their treating physician has planned to give immunotherapy are eligible for this study; this can be in the setting of a clinical trial or notXx_NEWLINE_xXPlanned curative intent chemotherapy, delivered either concurrently or sequentially in combination with radiotherapyXx_NEWLINE_xXFor cohort A, only patients for whom their neuro-oncologist has planned to give bevacizumab with lomustine are eligible for this studyXx_NEWLINE_xXFor cohort B, only patients for whom their neuro-oncologist has planned to give bevacizumab monotherapy are eligible for this studyXx_NEWLINE_xXSubjects with significant concurrent medical complications that in the judgment of the principal investigator(s) could affect the patient's ability to complete the planned trial, including the multiple imaging studiesXx_NEWLINE_xXPlanned SRT for recurrence after primary prostatectomy.Xx_NEWLINE_xXPlanned standard of care surgeryXx_NEWLINE_xXPrior radiation therapy which would provide significant dose overlap with the planned target volume(s) delivered within 30 days of enrollment or registrationXx_NEWLINE_xXPatients with minimal FDG-avidity localized to the planned treatment target (e.g. maximum standardized uptake value [SUV] < 4.0)Xx_NEWLINE_xXCohort B only: (N = 5 evaluable patients): Planned nephrectomy within 12 weeks following protocol scanXx_NEWLINE_xXPatients getting a planned wedge resection as the only thoracic resectional procedureXx_NEWLINE_xXPlanned standard of care surgery with curative intent for pancreatic adenocarcinomaXx_NEWLINE_xXPlanned administration of any NET therapy between scan 1 and 2, except for short acting octreotideXx_NEWLINE_xXSUB-STUDY II: Planned salvage external beam radiation therapyXx_NEWLINE_xXStandard of care CT abdomen examination planned with intravenous (IV) contrast.Xx_NEWLINE_xXHave standard of care biopsy or resection planned or tumors amenable to serial biopsies.Xx_NEWLINE_xXMen with prostate cancer and known bone metastases planned for new systemic therapy and/or radiotherapy and who have a planned clinically indicated staging multi-detector computed tomography (MDCT)Xx_NEWLINE_xXPlanned treatment with agent targeting PI3K/mTOR pathway (either standard of care or investigational agent)Xx_NEWLINE_xXPlanned or ongoing treatment with an androgen signaling inhibitor (e.g., abiraterone, enzalutamide, ARN-509) or another systemic therapy for mCRPCXx_NEWLINE_xXPlanned radical prostatectomy at Memorial Sloan-Kettering Cancer Center (MSKCC)Xx_NEWLINE_xXMultiparametric MRI of the pelvis (performed or planned) as routine careXx_NEWLINE_xXPlanned radical prostatectomy at UCSF within 12 weeks following protocol MRI/MRSIXx_NEWLINE_xXParticipants with thyroid carcinoma or thyroid disease for whom systemic radioactive iodine therapy is part of planned diagnostic work-up or treatment within 2 months following the contrast mammogram studyXx_NEWLINE_xXPlanned craniotomy and resection or biopsyXx_NEWLINE_xXParticipant must be receiving a planned lymphoscintigraphy procedureXx_NEWLINE_xXPlanned total mastectomy for treatmentXx_NEWLINE_xXPlanned standard of care surgery with curative intent for squamous cell carcinomaXx_NEWLINE_xXPresently planned for ongoing octreotide according to current standard of care for at least 12 months (i.e. throughout the study follow-up period)Xx_NEWLINE_xXParticipant with unilateral or bilateral neck dissection planned for care; an N0 neck must be planned to be dissected for the patient to be eligible; the N0 neck can be either ipsilateral to the head and neck tumor or the contralateral N0 neck if a bilateral neck dissection is plannedXx_NEWLINE_xXPlanned standard of care surgery with curative intent for pancreatic adenocarcinomaXx_NEWLINE_xXPatients must have planned treatment with doxorubicin:\r\n* Patients with sarcoma must have an initial planned regimen including 75 mg/m^2 doxorubicin for at least 4 cycles; NOTE: patients can be on additional chemotherapeutic agents \r\n* Patients with lymphoma must have an initial planned regimen including 50 mg/m^2of doxorubicin for at least 6 cycles; NOTE: patients can be on additional chemotherapeutic agents\r\n* Patients with breast cancer must have an initial planned regimen including 60 mg/m^2 of doxorubicin for at least 4 cycles; breast cancer patient enrollment will stop once 60 breast cancer patients have been enrolled; NOTE: patients can be on additional chemotherapeutic agentsXx_NEWLINE_xXThyroidectomy or lobectomy planned as definitive treatment for thyroid cancer or patients on active surveillance management approachXx_NEWLINE_xXPlanned procedures or therapies in between SOC scans and study scan on s-DCT, e.g., biopsy or excision of lung lesionXx_NEWLINE_xXPlanned standard of care surgery with curative intent for squamous cell carcinomaXx_NEWLINE_xXAny history of radiotherapy to the chest prior to systemic therapy or planned consolidation chest radiation therapy (except paliative care outside of the chest).Xx_NEWLINE_xXPlanned thorascopic, robotic or laparoscopic surgical approachXx_NEWLINE_xXPlanned standard of care surgeryXx_NEWLINE_xXPlanned for treatment with radiation, chemotherapy and surgical resection or any of these treatment strategies combinedXx_NEWLINE_xXAll pathology specimens must be within 1 year of the planned 18F-FSPG PET/CT scan.Xx_NEWLINE_xXNeoadjuvant chemoradiation prior to resection is plannedXx_NEWLINE_xXSubjects must be planned for resection (this includes localized resectable disease or patients with metastatic disease with planned palliative resection) and scheduled to begin neoadjuvant chemotherapyXx_NEWLINE_xXPatients must be planned for at least 45 Gy of thoracic radiationXx_NEWLINE_xXPatients must not be planned for lung resection after radiation therapyXx_NEWLINE_xXCohort A only (N = 5 evaluable patients):- Planned radical prostatectomy within 12 weeks following protocol scanXx_NEWLINE_xXNo international travel planned during the next 4 monthsXx_NEWLINE_xXOff study use of ketorolac or other NSAIDs prior to study administration within the perioperative window (7 days before surgery and up to the time of planned study administration)Xx_NEWLINE_xXPlanned quit date within the next two monthsXx_NEWLINE_xXAdenocarcinoma of the prostate with planned radical prostatectomy (RP) with curative intent as part of standard of care management planXx_NEWLINE_xXSerum albumin must be planned to be collected after admission, but prior to treatmentXx_NEWLINE_xXPatients who underwent, currently undergoing or planned to start radiation treatment with curative, adjuvant or palliative intent, who have not yet had their first post-treatment visitXx_NEWLINE_xXDiagnosed Head and Neck Cancer patients with planned Radiation therapyXx_NEWLINE_xXPlanned RT to the head/neckXx_NEWLINE_xXPatients must not be on enzalutamide within five half-lives before the first planned dose of the study drug or anticipating to start enzalutamide within the next 3 months of the first planned dose of study drugXx_NEWLINE_xXPrevious exposure to OTL38 2. Known FR-negative ovarian cancer 3. Planned surgical debulking via laparoscopy or robotic surgery, with no intent of laparotomy.Xx_NEWLINE_xXPatients diagnosed with bladder cancer with planned cystectomy and urinary diversion, +/- neoadjuvant chemotherapyXx_NEWLINE_xXstage II-III, planned to be treated with radical surgeryXx_NEWLINE_xXPlanned surgical approach via laparoscopy or robotic surgeryXx_NEWLINE_xXPatient is currently undergoing AML-like intensive induction, re-induction/salvage, or consolidation chemotherapy, or planned to start such therapy within 1 weekXx_NEWLINE_xX